Clinical Trial Update: Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC [EARLY_Phase 1]

View source ↗

Summary

An early-phase study is evaluating sequential bortezomib, pembrolizumab, and cisplatin in metastatic triple-negative breast cancer. The trial is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• Velcade (bortezomib)

Snippet

Sponsor: Baylor Research Institute | Conditions: Breast Cancer | EARLY_Phase 1 | Status: RECRUITING